Emcure Pharmaceuticals’ shares declined 3 percent on Tuesday after a large block trade triggered selling pressure in early hours. Around 40.6 lakh shares, representing about 2.4 percent of the company’s equity, changed hands across two block deals on the exchanges.

The transaction is likely linked to Bain Capital’s BC Investments, which, according to earlier reports, was expected to offload up to 2 percent of its stake in the pharma major. Emcure Pharma shares were trading at Rs 1,352 around 11 am, extending the stock’s weak trend for 2025, during which it has fallen about 7.5 percent year to date.

Block Deal Details

A CNBC TV18 report on Monday indicated that BC Investments (Bain Capital) had planned to sell up to 2 percent of Emcure Pharma’s total equity through a block deal at a floor price of Rs 1,296.51 per share.
This price implied a 7 percent discount to Monday’s closing level of Rs 1,394.10 on the NSE.

The total deal value was estimated at up to Rs 493 crore, with a 90-day lock-in applicable to the shares sold. As of the end of Q2 2025, BC Asia held a 6.3 percent stake in Emcure Pharma.

Final confirmation on the seller and details of the buyers will be available once exchange disclosures are published.

Also Read: Budget May Peg FY27 Fiscal Deficit Target Modestly Lower Than 4.4%

Company’s Q2 Performance

Despite the stock volatility, Emcure Pharmaceuticals delivered a strong July–September (Q2) quarter:

Net profit: Rs 243 crore, up 25.1% YoY (vs Rs 194 crore last year)
Revenue: Rs 2,269.8 crore, up 13.4% YoY
EBITDA: Rs 475.4 crore, up 25% YoY
EBITDA margin: Improved to 21% (from 19%)

The company attributed its growth to broad-based demand across key therapeutic areas, including gynaecology, cardiovascular, HIV antivirals, pain management, and increased traction in domestic and international markets.
Momentum in the Indian formulations business and healthy demand from emerging markets through new launches and regulatory filings also supported performance.

Click here to explore:
Gift Nifty
FII DII Data
IPO

Share This Article

ByPradeep Sangatramani

Follow:

Pradeep Sangatramani, founder and CEO of NiftyTrader, is an IIM Calcutta alumnus with a background in engineering. Passionate about the stock market from early on, he spent years studying its dynamics and working in roles focused on market analysis, trading tools, and financial data. Realising the challenges traders face in accessing user-friendly tools, he built NiftyTrader to offer data-driven, easy-to-use solutions. Committed to transparency and education, Pradeep actively shares insights through articles and webinars, aiming to empower traders at all levels.